MedTrace Logo

Evaluating the Results of Physician and Parent Decisions to Treat Selective Mutism With Fluoxetine

NCT05378711 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2022-05-18

No results posted yet for this study

Summary

The Department of Counseling, Educational Psychology, and Special Education and the Department of Psychiatry at Michigan State University have coordinated efforts to provide a diagnostic and treatment investigation for children, ages seven to eighteen, with Selective Mutism. The purpose of this study is to examine the utility of fluoxetine for the treatment of this debilitating disorder. Fluoxetine is expected to improve social anxiety and selective mutism symptomology.

Conditions

  • Selective Mutism
  • Social Anxiety

Interventions

DRUG

Fluoxetine

Children will receive a placebo or fluoxetine at different times dependent upon random assignment to a treatment schedule.

Sponsors & Collaborators

Principal Investigators

  • Jed Magen, DO · Michigan State University

  • John Carlson, PhD · Michigan State University

  • Justin Barterian, MA · Michigan State University

  • Joel Sanchez, MD · Michigan State University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
5 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-01
Primary Completion
2015-05-30
Completion
2015-05-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05378711 on ClinicalTrials.gov